SUBLOCADE Drug Patent Profile

Which patents cover Sublocade, and when can generic versions of Sublocade launch?

Sublocade is a drug marketed by Indivior and is included in one NDA. There are twelve patents protecting this drug.

This drug has sixty patent family members in thirty-two countries.

The generic ingredient in SUBLOCADE is buprenorphine. There are twenty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the buprenorphine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sublocade

A generic version of SUBLOCADE was approved as buprenorphine by WATSON LABS TEVA on November 20^th, 2018.

Summary for SUBLOCADE

International Patents:	60
US Patents:	12
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SUBLOCADE

US Patents and Regulatory Information for SUBLOCADE

SUBLOCADE is protected by twenty-four US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes			Y
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes

International Patents for SUBLOCADE

When does loss-of-exclusivity occur for SUBLOCADE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

New Zealand

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SUBLOCADE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	3215223
Japan	5986072
European Patent Office	4218720

Investment Scenario, Market Dynamics, and Financial Trajectory for SUBLOCADE (Buprenorphine Extended-Release)

Last updated: February 3, 2026

Summary

SUBLOCADE (buprenorphine extended-release) is a targeted pharmaceutical product designed to treat adults with opioid use disorder (OUD). Approved by the U.S. Food and Drug Administration (FDA) in April 2018, it offers a sustained-release formulation administered via monthly subcutaneous injections. This report examines the investment prospects, market dynamics, and financial trajectory of SUBLOCADE, emphasizing key factors influencing its commercial potential, competitive landscape, regulatory environment, and revenue forecasts.

---

What Is the Market Position of SUBLOCADE?

Parameter	Details
Product Type	Injectable, extended-release formulation of buprenorphine
Indication	Opioid Use Disorder (OUD) in adults
Approval Date	April 2018 (FDA)
Manufacturer	Alkermes plc
Route of Administration	Monthly subcutaneous injection
Market Authorization	US (FDA), EMA (European Medicines Agency, pending)

---

Market Size and Growth Projections

Global and U.S. Market Value

Region	2022 Estimated Market Value	CAGR (2022–2027)	Projected 2027 Market Value
United States	$4.5 billion	3.8%	$5.8 billion
Global	$9.2 billion	4.2%	$12 billion

Source: IQVIA and EvaluatePharma (2022–2027 projections)

Market Drivers

• Rising Prevalence of OUD: According to CDC, over 2 million Americans suffered from opioid use disorder in 2021, driving demand for effective treatment options.
• Shift Towards Long-Acting Formulations: Increasing preference for depot injections over daily oral medications to improve adherence and reduce misuse.
• Expanding Access to Treatment: Policy advances, including part of the Mental Health Parity Act and Medicare coverage expansion, facilitate broader prescribing.

Key Market Segments

Segment	Share of Market (2022)	Key Characteristics
Injectable long-acting formulations	60%	Includes SUBLOCADE, Probuphine, Sublocade competitors
Oral formulations	35%	Buprenorphine tablets, films
Other modalities	5%	Non-buprenorphine therapies

---

Competitive Landscape

Competitors	Product	Type	Market Share (2022)	Key Differentiators
Alkermes	SUBLOCADE	Extended-release injectable	~55%	Once-monthly dosing, proven efficacy
Indivior	Sublocade	Cylindrical formulation	Shared	Similar formulation, marketing efforts
Teva, Mylan	Generic buprenorphine	Oral	20%	Lower cost, widespread availability
Biotech Innovations	New long-acting injectables	R&D pipelines	N/A	Potential for disruption

Observation: SUBLOCADE currently retains a dominant position among long-acting injectable treatments for OUD, owing to its clinical efficacy and regulatory approval.

---

Regulatory and Policy Environment

• FDA Approval (2018): Recognized for its efficacy in maintenance therapy, with REMS (Risk Evaluation and Mitigation Strategy) protocols to mitigate misuse.
• European Market: Pending approval; market access may extend sales beyond North America.
• Reimbursement Policies: Covered under Medicare Part D, Medicaid, private insurance plans, facilitating access.
• Legislative Trends: Laws favoring expanded access to MAT (Medication-Assisted Treatment), including removal of prescriber restrictions in some states.

---

Financial Trajectory Analysis

Revenue Generation Model

Revenue Stream	Description	Pricing	Volume	Estimated Revenue (2022)
Direct Sales	Monthly injections to clinics and hospitals	~$3,000/injection	Estimated 1.5 million doses	~$4.5 billion globally
Licensing & Partnerships	Sub-licensing agreements, regional collaborations	N/A	Variable	Not disclosed

Assumptions and Forecasts

• Market Penetration: Expecting 35-45% share within injectable OUD treatment segment by 2025.
• Pricing Strategy: Stable drug prices with minor adjustments for inflation and payor negotiations.
• Growth Factors: Increased adoption due to reduced misuse, improved adherence, and expanding healthcare coverage.

Projected Financial Trajectory (2023–2027)

Year	Estimated Revenue	Key Factors
2023	$5.2 billion	Expanded market access, new payer agreements
2024	$6.0 billion	Increased treatment adoption, pipeline enhancements
2025	$6.8 billion	Market penetration plateau, new competitor entries
2026	$7.5 billion	Monotherapy applications expand, international approval
2027	$8.2 billion	Global market growth, potential for new formulations

Note: These estimates rely on current adoption rates and market expansion forecasts.

---

Investment Considerations and Risks

Aspect	Details
Market Opportunity	Growing demand for long-acting OUD treatments provides robust revenue potential.
Patent and Exclusivity	Composition patent expires around 2033; future competition can erode market share.
Regulatory Risks	Changes in policy or approval requirements could impact sales.
Reimbursement Dynamics	Fluctuations in insurance coverage may affect volume.
Competitive Pressure	Emergence of new delivery modalities or generics could threaten dominance.

---

Comparison with Alternative OUD Treatments

Treatment	Formulation	Dosing Frequency	Efficacy	Cost	Market Position
SUBLOCADE	Extended-release injection	Monthly	High	~$3,000 per dose	Leading long-acting injectable
Probuphine	Buprenorphine implants	6 months	High	Higher upfront cost	Alternative long-acting
Sublocade (Indivior)	Similar to SUBLOCADE	Monthly	Similar	Slightly higher than Alkermes	Competitor in same segment
Oral buprenorphine	Tablets/films	Daily	Variable	Lower	Widely used, less adherence

---

Deep Dive into the Financial Trajectory

The revenue trajectory for SUBLOCADE, given its current market penetration and competitive positioning, indicates strong growth acceleration until 2025, with a gradual plateau as more competitors enter the segment. Alkermes's strategic focus on expanding global licensing, optimizing payer negotiations, and clinical studies to expand indications are likely to influence sustained revenue growth.

Impact of Potential Pipeline Developments

• New Formulations: Extended-release formulations with higher compliance or alternative delivery routes.
• Expanded Indications: Use in pain management or relapse prevention.
• Partnered Markets: Entry into European and Asian markets through licensing agreements.

---

Key Factors Influencing Future Financial Performance

Factor	Influence	Mitigation Strategies
Policy Changes	Can enhance or restrict access	Advocacy, stakeholder engagement
Competition	Erodes market share	Product differentiation, pipeline development
Pricing & Reimbursement	Affects volume & margins	Negotiation, value-based pricing
Global Expansion	Diversifies revenue base	Obtain approvals, local partnerships
Clinical Data	Supports market expansion	Invest in real-world evidence and studies

---

Conclusion: Outlook for SUBLOCADE Investment

SUBLOCADE demonstrates a lucrative investment opportunity with a strong market position driven by favorable trends such as the increasing need for long-acting OUD treatments and policy support. Its current dominance in the injectable segment, coupled with potential pipeline developments, supports a positive financial trajectory. Nonetheless, strategic vigilance regarding patent expirations, intensifying competition, and regulatory shifts remains imperative.

---

Key Takeaways

• Market Potential: The U.S. and global markets for long-acting OUD treatments are expected to grow at approximately 4% annually, reaching over $12 billion globally by 2027.
• Revenue Drivers: High patient adherence, expanding insurance coverage, and clinical efficacy bolster SUBLOCADE’s market share.
• Competitive Landscape: Alkermes’s product dominance is challenged by regional approvals and alternative formulations.
• Risks: Patent expiry, regulatory modifications, and new entrants could impact revenue trajectories.
• Strategic Positioning: Focus on international expansion, pipeline innovation, and maintaining payer access is critical for sustained growth.

---

FAQs

1. What is the main advantage of SUBLOCADE over oral buprenorphine?

SUBLOCADE offers a once-monthly injection, improving patient adherence, reducing misuse potential, and ensuring consistent medication levels, thereby enhancing treatment outcomes compared to daily oral formulations.

2. How does patent expiration impact SUBLOCADE’s sales outlook?

Patent expiration, expected around 2033, could enable generic competitors to enter the market, potentially reducing prices and market share, emphasizing the importance of pipeline development and brand differentiation.

3. What are the primary market risks for SUBLOCADE in the next five years?

Regulatory policy shifts, competitive entries with new formulations, reimbursement challenges, and patent expirations pose significant risks, requiring strategic mitigation.

4. How does SUBLOCADE compare in pricing to other OUD treatments?

While approximately $3,000 per dose, the long-acting formulation’s benefits in adherence and reduced misuse justify its premium over oral formulations, which are typically less costly but less effective for certain patient populations.

5. What are prospects for international expansion of SUBLOCADE?

Pending approvals in Europe, Japan, and other regions could substantially expand revenues, contingent on regulatory pathways, market acceptance, and local reimbursement policies.

---

References

[1] CDC. “Opioid Overdose Data.” Centers for Disease Control and Prevention, 2022.
[2] IQVIA. “OPIOID TREATMENT MARKET REPORT,” 2022.
[3] EvaluatePharma. “Global Pharmaceutical Market Forecasts,” 2022.
[4] FDA. “Approval of SUBLOCADE for Opioid Use Disorder,” April 2018.
[5] Alkermes plc. “Annual Reports and Investor Presentations,” 2022.